Actively Recruiting
Multicenter Observational Study Evaluating HER2 IHC Test Agreement in Chinese Patients with NSCLC, Gynecological, Biliary Tract, and Urothelial Cancers
Led by AstraZeneca · Updated on 2026-10-28
2100
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, non-interventional, descriptive study to collect and analyze tumor samples from patients with various solid tumors, including non-small cell lung cancer NSCLC, gynecological cancers, biliary tract cancer BTC, and urothelial carcinoma UC. The study aims to assess the agreement between different laboratory tests for HER2 protein expression using immunohistochemistry IHC in Chinese pan-tumor patients. This research includes about 2100 patients diagnosed between January 2023 and September 2025 across 12 sites. The study has two phases enrollment and assessment. During enrollment, retrospective collection of tumor samples occurs, and HER2 status is tested locally using the Roche 4B5 assay. A committee reviews these results. In the assessment phase, 320 patients are selected to represent different HER2 expression levels across the tumor types. Tissue samples are sectioned and tested by multiple assays at central laboratories, and digital images of some slides are interpreted by 36 trained pathologists to evaluate consistency between tests and interpretations. Participants contribute by providing archived tumor tissue samples with sufficient slides for HER2 testing. The study evaluates the agreement between different HER2 testing assays and the consistency among pathologists interpreting these results. Researchers measure various concordance outcomes over approximately six months, including positive and negative percent agreements and inter-observer agreement. The study does not involve any treatment, and participant involvement mainly consists of sample provision and data collection from existing records.
CONDITIONS
Brief Title
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here